235 related articles for article (PubMed ID: 29926531)
1. ARNT/HIF-1β links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma.
Wu C; Yang T; Liu Y; Lu Y; Yang Y; Liu X; Liu X; Ye L; Sun Y; Wang X; Li Q; Yang P; Yu X; Gao S; Kumar S; Jin F; Dai Y; Li W
Cancer Med; 2018 Aug; 7(8):3899-3911. PubMed ID: 29926531
[TBL] [Abstract][Full Text] [Related]
2. HIF-1β Positively Regulates NF-κB Activity via Direct Control of TRAF6.
D'Ignazio L; Shakir D; Batie M; Muller HA; Rocha S
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32344511
[TBL] [Abstract][Full Text] [Related]
3. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
4. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible aryl hydrocarbon receptor nuclear translocator (ARNT) (HIF-1β): is it a rare exception?
Mandl M; Depping R
Mol Med; 2014 May; 20(1):215-20. PubMed ID: 24849811
[TBL] [Abstract][Full Text] [Related]
6. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
7. Aryl hydrocarbon receptor nuclear translocator/hypoxia-inducible factor-1{beta} plays a critical role in maintaining glucose-stimulated anaplerosis and insulin release from pancreatic {beta}-cells.
Pillai R; Huypens P; Huang M; Schaefer S; Sheinin T; Wettig SD; Joseph JW
J Biol Chem; 2011 Jan; 286(2):1014-24. PubMed ID: 21059654
[TBL] [Abstract][Full Text] [Related]
8. The Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT/HIF-1β) is influenced by hypoxia and hypoxia-mimetics.
Wolff M; Jelkmann W; Dunst J; Depping R
Cell Physiol Biochem; 2013; 32(4):849-58. PubMed ID: 24081025
[TBL] [Abstract][Full Text] [Related]
9. Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Apoptosis; 2016 Dec; 21(12):1422-1437. PubMed ID: 27734217
[TBL] [Abstract][Full Text] [Related]
10. A HIF-1α-driven feed-forward loop augments HIF signalling in Hep3B cells by upregulation of ARNT.
Mandl M; Lieberum MK; Depping R
Cell Death Dis; 2016 Jun; 7(6):e2284. PubMed ID: 27362802
[TBL] [Abstract][Full Text] [Related]
11. The expression level of the transcription factor Aryl hydrocarbon receptor nuclear translocator (ARNT) determines cellular survival after radiation treatment.
Mandl M; Lieberum M; Dunst J; Depping R
Radiat Oncol; 2015 Nov; 10():229. PubMed ID: 26572229
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of 1q21 Gain in Multiple Myeloma.
Chen D; Zhou D; Xu J; Zhou R; Ouyang J; Chen B
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):e159-e164. PubMed ID: 30685183
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
Fonseca R; Van Wier SA; Chng WJ; Ketterling R; Lacy MQ; Dispenzieri A; Bergsagel PL; Rajkumar SV; Greipp PR; Litzow MR; Price-Troska T; Henderson KJ; Ahmann GJ; Gertz MA
Leukemia; 2006 Nov; 20(11):2034-40. PubMed ID: 17024118
[TBL] [Abstract][Full Text] [Related]
14. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
[TBL] [Abstract][Full Text] [Related]
15. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.
Muz B; Kusdono HD; Azab F; de la Puente P; Federico C; Fiala M; Vij R; Salama NN; Azab AK
Leuk Lymphoma; 2017 Dec; 58(12):2916-2925. PubMed ID: 28509582
[TBL] [Abstract][Full Text] [Related]
16. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia.
Sun HL; Liu YN; Huang YT; Pan SL; Huang DY; Guh JH; Lee FY; Kuo SC; Teng CM
Oncogene; 2007 Jun; 26(27):3941-51. PubMed ID: 17213816
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
Slomp A; Moesbergen LM; Gong JN; Cuenca M; von dem Borne PA; Sonneveld P; Huang DCS; Minnema MC; Peperzak V
Blood Adv; 2019 Dec; 3(24):4202-4214. PubMed ID: 31856269
[TBL] [Abstract][Full Text] [Related]
18. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition.
Choi H; Chun YS; Kim SW; Kim MS; Park JW
Mol Pharmacol; 2006 Nov; 70(5):1664-71. PubMed ID: 16880289
[TBL] [Abstract][Full Text] [Related]
19. Cloning, characterization, hypoxia and heat shock response of hypoxia inducible factor-1 (HIF-1) from the small abalone Haliotis diversicolor.
Cai X; Huang Y; Zhang X; Wang S; Zou Z; Wang G; Wang Y; Zhang Z
Gene; 2014 Jan; 534(2):256-64. PubMed ID: 24211325
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
An G; Xu Y; Shi L; Shizhen Z; Deng S; Xie Z; Sui W; Zhan F; Qiu L
Haematologica; 2014 Feb; 99(2):353-9. PubMed ID: 24213147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
